{"id":5516,"date":"2023-11-09T06:45:26","date_gmt":"2023-11-09T12:45:26","guid":{"rendered":"https:\/\/nanostherapeutics.com\/?p=5516"},"modified":"2025-06-27T11:28:27","modified_gmt":"2025-06-27T16:28:27","slug":"nanoscope-therapeutics-to-present-at-the-4th-annual-dry-amd-therapeutic-development-summit","status":"publish","type":"post","link":"https:\/\/nanostherapeutics.com\/es\/2023\/11\/09\/nanoscope-therapeutics-to-present-at-the-4th-annual-dry-amd-therapeutic-development-summit\/","title":{"rendered":"Nanoscope Therapeutics se presentar\u00e1 en la 4\u00aa Cumbre Anual de Desarrollo Terap\u00e9utico de AMD Seca"},"content":{"rendered":"
\n

<\/h1>\n<\/div>\n
\n
\n
\n
\n

DALLAS<\/span><\/span>,\u00a09 de noviembre de 2023<\/span><\/span>\u00a0 \u2014 Nanoscopio Therapeutics Inc.<\/a>, una empresa de biotecnolog\u00eda en etapa cl\u00ednica que desarrolla terapias gen\u00e9ticas para enfermedades hereditarias de la retina y degeneraciones maculares relacionadas con la edad (DMAE), anunci\u00f3 hoy que el Dr.\u00a0Samarendra Mohanty<\/span>, Presidente y Director Cient\u00edfico participar\u00e1n en un panel y estar\u00e1n presentes en la\u00a04th<\/sup>\u00a0Cumbre anual de desarrollo terap\u00e9utico de AMD seca<\/a>\u00a0teniendo lugar desde\u00a014-16 de noviembre de 2023<\/span>\u00a0en\u00a0Boston, Massachusetts<\/span>. Los detalles del panel y la presentaci\u00f3n son los siguientes:<\/p>\n

T\u00edtulo:<\/b>\u00a0Superar las limitaciones de la DMAE seca sin tener un modelo de enfermedad reconocido
Sesi\u00f3n:\u00a0<\/b>C\u00f3mo optimizar los modelos actuales de DMAE seca in vivo e in vitro para mejorar la eficacia.
Fecha de la sesi\u00f3n:\u00a0<\/b>15 de noviembre de 2023<\/span>
Tiempo de sesi\u00f3n:\u00a0<\/b>11:00 am hora del este<\/span>
Ubicaci\u00f3n:\u00a0<\/b>Hilton Boston-Logan Airport<\/p>\n

Durante la mesa redonda, el Dr. Mohanty destacar\u00e1 las razones por las que desarrollar un modelo animal relevante para la DMAE seca sigue siendo un desaf\u00edo pertinente. Tambi\u00e9n explorar\u00e1 formas de incorporar m\u00e1s NHP en pruebas precl\u00ednicas para informar mejor el perfil de seguridad de las terapias para la DMAE seca.<\/p>\n

T\u00edtulo:\u00a0<\/b>Ampliaci\u00f3n de la restauraci\u00f3n de la visi\u00f3n mediante optogen\u00e9tica a GA mediante la administraci\u00f3n l\u00e1ser de opsina multicaracter\u00edstica
Sesi\u00f3n:\u00a0<\/b>Investigaci\u00f3n de los \u00faltimos avances para mejorar la administraci\u00f3n de terapias para la DMAE seca
Fecha de la sesi\u00f3n:\u00a0<\/b>16 de noviembre de 2023<\/span>
Tiempo de sesi\u00f3n:\u00a0<\/b>4:00 p.m. hora del este<\/span>
Ubicaci\u00f3n:\u00a0<\/b>Hilton Boston-Logan Airport<\/p>\n

En su presentaci\u00f3n, el Dr. Mohanty analizar\u00e1 las posibilidades de la optogen\u00e9tica para mejorar la agudeza visual en pacientes con degeneraci\u00f3n macular, bas\u00e1ndose en datos de prueba de concepto obtenidos en humanos, y evaluar\u00e1 los datos precl\u00ednicos m\u00e1s recientes sobre el uso de la administraci\u00f3n l\u00e1ser de opsina multicaracter\u00edstica (MCO). Asimismo, abordar\u00e1 el potencial de la plataforma para el tratamiento de diversas afecciones degenerativas de la retina.<\/p>\n

Acerca de Nanoscope Therapeutics Inc.
<\/b>Nanoscope Therapeutics est\u00e1 desarrollando terapias optogen\u00e9ticas que restauran la vista y son independientes de los genes para los millones de pacientes cegados por enfermedades hereditarias de la retina, para las cuales no existe cura. El activo principal de la compa\u00f1\u00eda, MCO-010, inform\u00f3 recientemente los resultados principales del ensayo cl\u00ednico RESTORE Fase 2b, multic\u00e9ntrico, aleatorizado, de doble enmascaramiento y controlado de forma simulada en los EE. UU. para la retinosis pigmentaria (NCT04945772<\/a>). La compa\u00f1\u00eda tambi\u00e9n complet\u00f3 recientemente su visita de fin de estudio para el ensayo de fase 2 STARLIGHT de la terapia MCO-010 en pacientes Stargardt (NCT05417126<\/a>). MCO-010 ha recibido designaciones de v\u00eda r\u00e1pida de la FDA y designaciones de medicamento hu\u00e9rfano de la FDA tanto para la retinitis pigmentosa como para la enfermedad de Stargardt. Los activos precl\u00ednicos incluyen la terapia g\u00e9nica MCO-020 administrada con l\u00e1ser no viral para la atrofia geogr\u00e1fica secundaria a la DMAE.<\/p>\n

Contacto de inversores:<\/b>
Socios Argot
212-600-1902
PR@nanostherapeutics.com<\/a><\/p>\n

FUENTE Terap\u00e9utica del Nanoscopio<\/p>\n<\/div>\n<\/div>\n<\/section>\n<\/article>","protected":false},"excerpt":{"rendered":"

DALLAS,\u00a0Nov. 9, 2023\u00a0 \u2014 Nanoscope Therapeutics Inc., a clinical-stage biotechnology company developing gene therapies for inherited retinal diseases and age-related macular degenerations (AMD), today announced that Dr.\u00a0Samarendra Mohanty, President and Chief Scientific Officer will participate in a panel and present at the\u00a04th\u00a0Annual Dry AMD Therapeutic Development Summit\u00a0taking place from\u00a0November 14-16, 2023\u00a0in\u00a0Boston, Massachusetts. Details for the […]<\/p>\n","protected":false},"author":6,"featured_media":5521,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_exactmetrics_skip_tracking":false,"_exactmetrics_sitenote_active":false,"_exactmetrics_sitenote_note":"","_exactmetrics_sitenote_category":0,"footnotes":"","_links_to":"","_links_to_target":""},"categories":[13,8],"tags":[],"class_list":["post-5516","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-home-page","category-nanoscope-press-release"],"yoast_head":"\nNanoscope Therapeutics to Present at the 4th Annual Dry AMD Therapeutic Development Summit - Nanoscope Therapeutics<\/title>\n<meta name=\"description\" content=\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nanostherapeutics.com\/es\/2023\/11\/09\/nanoscope-therapeutics-to-present-at-the-4th-annual-dry-amd-therapeutic-development-summit\/\" \/>\n<meta property=\"og:locale\" content=\"es_MX\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nanoscope Therapeutics to Present at the 4th Annual Dry AMD Therapeutic Development Summit - Nanoscope Therapeutics\" \/>\n<meta property=\"og:description\" content=\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nanostherapeutics.com\/es\/2023\/11\/09\/nanoscope-therapeutics-to-present-at-the-4th-annual-dry-amd-therapeutic-development-summit\/\" \/>\n<meta property=\"og:site_name\" content=\"Nanoscope Therapeutics\" \/>\n<meta property=\"article:published_time\" content=\"2023-11-09T12:45:26+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-06-27T16:28:27+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2023\/11\/NSCOPE_LI_Dry-AMD-Summit.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"1200\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Nanoscope Therapeutics\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:image\" content=\"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2023\/09\/NSCOPE_LI_Barone_final2.jpg\" \/>\n<meta name=\"twitter:creator\" content=\"@NSTherapeutics\" \/>\n<meta name=\"twitter:site\" content=\"@NSTherapeutics\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"Nanoscope Therapeutics\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2023\\\/11\\\/09\\\/nanoscope-therapeutics-to-present-at-the-4th-annual-dry-amd-therapeutic-development-summit\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2023\\\/11\\\/09\\\/nanoscope-therapeutics-to-present-at-the-4th-annual-dry-amd-therapeutic-development-summit\\\/\"},\"author\":{\"name\":\"Nanoscope Therapeutics\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/person\\\/5aeedc9aef0946fe8f96f98f7b1808a2\"},\"headline\":\"Nanoscope Therapeutics to Present at the 4th Annual Dry AMD Therapeutic Development Summit\",\"datePublished\":\"2023-11-09T12:45:26+00:00\",\"dateModified\":\"2025-06-27T16:28:27+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2023\\\/11\\\/09\\\/nanoscope-therapeutics-to-present-at-the-4th-annual-dry-amd-therapeutic-development-summit\\\/\"},\"wordCount\":386,\"publisher\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2023\\\/11\\\/09\\\/nanoscope-therapeutics-to-present-at-the-4th-annual-dry-amd-therapeutic-development-summit\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2023\\\/11\\\/NSCOPE_LI_Dry-AMD-Summit.jpg\",\"articleSection\":[\"Home Page\",\"Nanoscope Press Release\"],\"inLanguage\":\"es\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2023\\\/11\\\/09\\\/nanoscope-therapeutics-to-present-at-the-4th-annual-dry-amd-therapeutic-development-summit\\\/\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/2023\\\/11\\\/09\\\/nanoscope-therapeutics-to-present-at-the-4th-annual-dry-amd-therapeutic-development-summit\\\/\",\"name\":\"Nanoscope Therapeutics to Present at the 4th Annual Dry AMD Therapeutic Development Summit - Nanoscope Therapeutics\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2023\\\/11\\\/09\\\/nanoscope-therapeutics-to-present-at-the-4th-annual-dry-amd-therapeutic-development-summit\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2023\\\/11\\\/09\\\/nanoscope-therapeutics-to-present-at-the-4th-annual-dry-amd-therapeutic-development-summit\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2023\\\/11\\\/NSCOPE_LI_Dry-AMD-Summit.jpg\",\"datePublished\":\"2023-11-09T12:45:26+00:00\",\"dateModified\":\"2025-06-27T16:28:27+00:00\",\"description\":\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2023\\\/11\\\/09\\\/nanoscope-therapeutics-to-present-at-the-4th-annual-dry-amd-therapeutic-development-summit\\\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nanostherapeutics.com\\\/2023\\\/11\\\/09\\\/nanoscope-therapeutics-to-present-at-the-4th-annual-dry-amd-therapeutic-development-summit\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2023\\\/11\\\/09\\\/nanoscope-therapeutics-to-present-at-the-4th-annual-dry-amd-therapeutic-development-summit\\\/#primaryimage\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2023\\\/11\\\/NSCOPE_LI_Dry-AMD-Summit.jpg\",\"contentUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2023\\\/11\\\/NSCOPE_LI_Dry-AMD-Summit.jpg\",\"width\":1200,\"height\":1200},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2023\\\/11\\\/09\\\/nanoscope-therapeutics-to-present-at-the-4th-annual-dry-amd-therapeutic-development-summit\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/nanostherapeutics.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Nanoscope Therapeutics to Present at the 4th Annual Dry AMD Therapeutic Development Summit\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#website\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/\",\"name\":\"Nanoscope Therapeutics\",\"description\":\"Bringing Back the Light of Hope\",\"publisher\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\"},\"alternateName\":\"Nanoscope Therapeutics\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nanostherapeutics.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\",\"name\":\"Nanoscope Therapeutics, Inc\",\"alternateName\":\"Nanoscope Therapeutics\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/NSCOPE_Logo_Stack_2Color_512.png\",\"contentUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/NSCOPE_Logo_Stack_2Color_512.png\",\"width\":512,\"height\":435,\"caption\":\"Nanoscope Therapeutics, Inc\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/x.com\\\/NSTherapeutics\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/nanoscope\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/person\\\/5aeedc9aef0946fe8f96f98f7b1808a2\",\"name\":\"Nanoscope Therapeutics\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Nanoscope Therapeutics presentar\u00e1 sus productos en la 4\u00aa Cumbre Anual sobre el Desarrollo de Terapias para la Degeneraci\u00f3n Materna Seca (DMAE seca) - Nanoscope Therapeutics","description":"Nuestra plataforma de opsina multicaracter\u00edstica (MCO) es la primera en demostrar, en ensayos cl\u00ednicos, la capacidad de restaurar la visi\u00f3n en pacientes con enfermedades retinianas y p\u00e9rdida visual severa. Nanoscope ha desarrollado MCO-010, la primera y \u00fanica tecnolog\u00eda optogen\u00e9tica de amplio espectro, respuesta r\u00e1pida y ultrasensible para la restauraci\u00f3n de la visi\u00f3n, independiente del gen.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nanostherapeutics.com\/es\/2023\/11\/09\/nanoscope-therapeutics-to-present-at-the-4th-annual-dry-amd-therapeutic-development-summit\/","og_locale":"es_MX","og_type":"article","og_title":"Nanoscope Therapeutics to Present at the 4th Annual Dry AMD Therapeutic Development Summit - Nanoscope Therapeutics","og_description":"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.","og_url":"https:\/\/nanostherapeutics.com\/es\/2023\/11\/09\/nanoscope-therapeutics-to-present-at-the-4th-annual-dry-amd-therapeutic-development-summit\/","og_site_name":"Nanoscope Therapeutics","article_published_time":"2023-11-09T12:45:26+00:00","article_modified_time":"2025-06-27T16:28:27+00:00","og_image":[{"width":1200,"height":1200,"url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2023\/11\/NSCOPE_LI_Dry-AMD-Summit.jpg","type":"image\/jpeg"}],"author":"Nanoscope Therapeutics","twitter_card":"summary_large_image","twitter_image":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2023\/09\/NSCOPE_LI_Barone_final2.jpg","twitter_creator":"@NSTherapeutics","twitter_site":"@NSTherapeutics","twitter_misc":{"Escrito por":"Nanoscope Therapeutics","Tiempo de lectura":"2 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/nanostherapeutics.com\/2023\/11\/09\/nanoscope-therapeutics-to-present-at-the-4th-annual-dry-amd-therapeutic-development-summit\/#article","isPartOf":{"@id":"https:\/\/nanostherapeutics.com\/2023\/11\/09\/nanoscope-therapeutics-to-present-at-the-4th-annual-dry-amd-therapeutic-development-summit\/"},"author":{"name":"Nanoscope Therapeutics","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/person\/5aeedc9aef0946fe8f96f98f7b1808a2"},"headline":"Nanoscope Therapeutics to Present at the 4th Annual Dry AMD Therapeutic Development Summit","datePublished":"2023-11-09T12:45:26+00:00","dateModified":"2025-06-27T16:28:27+00:00","mainEntityOfPage":{"@id":"https:\/\/nanostherapeutics.com\/2023\/11\/09\/nanoscope-therapeutics-to-present-at-the-4th-annual-dry-amd-therapeutic-development-summit\/"},"wordCount":386,"publisher":{"@id":"https:\/\/nanostherapeutics.com\/#organization"},"image":{"@id":"https:\/\/nanostherapeutics.com\/2023\/11\/09\/nanoscope-therapeutics-to-present-at-the-4th-annual-dry-amd-therapeutic-development-summit\/#primaryimage"},"thumbnailUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2023\/11\/NSCOPE_LI_Dry-AMD-Summit.jpg","articleSection":["Home Page","Nanoscope Press Release"],"inLanguage":"es"},{"@type":"WebPage","@id":"https:\/\/nanostherapeutics.com\/2023\/11\/09\/nanoscope-therapeutics-to-present-at-the-4th-annual-dry-amd-therapeutic-development-summit\/","url":"https:\/\/nanostherapeutics.com\/2023\/11\/09\/nanoscope-therapeutics-to-present-at-the-4th-annual-dry-amd-therapeutic-development-summit\/","name":"Nanoscope Therapeutics presentar\u00e1 sus productos en la 4\u00aa Cumbre Anual sobre el Desarrollo de Terapias para la Degeneraci\u00f3n Materna Seca (DMAE seca) - Nanoscope Therapeutics","isPartOf":{"@id":"https:\/\/nanostherapeutics.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/nanostherapeutics.com\/2023\/11\/09\/nanoscope-therapeutics-to-present-at-the-4th-annual-dry-amd-therapeutic-development-summit\/#primaryimage"},"image":{"@id":"https:\/\/nanostherapeutics.com\/2023\/11\/09\/nanoscope-therapeutics-to-present-at-the-4th-annual-dry-amd-therapeutic-development-summit\/#primaryimage"},"thumbnailUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2023\/11\/NSCOPE_LI_Dry-AMD-Summit.jpg","datePublished":"2023-11-09T12:45:26+00:00","dateModified":"2025-06-27T16:28:27+00:00","description":"Nuestra plataforma de opsina multicaracter\u00edstica (MCO) es la primera en demostrar, en ensayos cl\u00ednicos, la capacidad de restaurar la visi\u00f3n en pacientes con enfermedades retinianas y p\u00e9rdida visual severa. Nanoscope ha desarrollado MCO-010, la primera y \u00fanica tecnolog\u00eda optogen\u00e9tica de amplio espectro, respuesta r\u00e1pida y ultrasensible para la restauraci\u00f3n de la visi\u00f3n, independiente del gen.","breadcrumb":{"@id":"https:\/\/nanostherapeutics.com\/2023\/11\/09\/nanoscope-therapeutics-to-present-at-the-4th-annual-dry-amd-therapeutic-development-summit\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nanostherapeutics.com\/2023\/11\/09\/nanoscope-therapeutics-to-present-at-the-4th-annual-dry-amd-therapeutic-development-summit\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/nanostherapeutics.com\/2023\/11\/09\/nanoscope-therapeutics-to-present-at-the-4th-annual-dry-amd-therapeutic-development-summit\/#primaryimage","url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2023\/11\/NSCOPE_LI_Dry-AMD-Summit.jpg","contentUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2023\/11\/NSCOPE_LI_Dry-AMD-Summit.jpg","width":1200,"height":1200},{"@type":"BreadcrumbList","@id":"https:\/\/nanostherapeutics.com\/2023\/11\/09\/nanoscope-therapeutics-to-present-at-the-4th-annual-dry-amd-therapeutic-development-summit\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/nanostherapeutics.com\/"},{"@type":"ListItem","position":2,"name":"Nanoscope Therapeutics to Present at the 4th Annual Dry AMD Therapeutic Development Summit"}]},{"@type":"WebSite","@id":"https:\/\/nanostherapeutics.com\/#website","url":"https:\/\/nanostherapeutics.com\/","name":"Terap\u00e9utica del nanoscopio","description":"Recuperando la luz de la esperanza","publisher":{"@id":"https:\/\/nanostherapeutics.com\/#organization"},"alternateName":"Nanoscope Therapeutics","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nanostherapeutics.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/nanostherapeutics.com\/#organization","name":"Nanoscope Therapeutics, Inc","alternateName":"Nanoscope Therapeutics","url":"https:\/\/nanostherapeutics.com\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/logo\/image\/","url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_Logo_Stack_2Color_512.png","contentUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_Logo_Stack_2Color_512.png","width":512,"height":435,"caption":"Nanoscope Therapeutics, Inc"},"image":{"@id":"https:\/\/nanostherapeutics.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/NSTherapeutics","https:\/\/www.linkedin.com\/company\/nanoscope"]},{"@type":"Person","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/person\/5aeedc9aef0946fe8f96f98f7b1808a2","name":"Terap\u00e9utica del nanoscopio"}]}},"_links":{"self":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts\/5516","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/comments?post=5516"}],"version-history":[{"count":3,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts\/5516\/revisions"}],"predecessor-version":[{"id":9063,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts\/5516\/revisions\/9063"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/media\/5521"}],"wp:attachment":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/media?parent=5516"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/categories?post=5516"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/tags?post=5516"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}